公开(公告)号：US20120065402A1

公开(公告)日：2012-03-15

申请号：US13299845

申请日：2011-11-18

Applicant: NORMAN HERRON ,  Mark A. Guidry ,  Vsevolod Rostovtsev ,  Weiying Gao ,  Ying Wang ,  Yulong Shen ,  Jeffrey A. Merlo

Inventor： NORMAN HERRON ,  Mark A. Guidry ,  Vsevolod Rostovtsev ,  Weiying Gao ,  Ying Wang ,  Yulong Shen ,  Jeffrey A. Merlo

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D201/00 ,  C07D471/16 ,  H01L51/0061 ,  H01L51/0072 ,  H01L51/5012 ,  H01L51/5024 ,  H01L51/5052 ,  H01L51/5072 ,  H01L2251/5384

Abstract: There is provided an organic electronic device having an anode, a hole injection layer, a photoactive layer, an electron transport layer, and a cathode. At least one of the photoactive layer and the electron transport layer includes a compound having Formula I where: R1 is the same or different and can be phenyl, biphenyl, naphthyl, naphthylphenyl, triphenylamino, or carbazolylphenyl; and one of the following conditions is met: (i) R2=R3 and is H, phenyl, biphenyl, naphthyl, naphthylphenyl, arylanthracenyl, phenanthryl, triphenylamino, or carbazolylphenyl; or (ii) R2 is H or phenyl; and R3 is phenyl, biphenyl, naphthyl, naphthylphenyl, arylanthracenyl, phenanthryl, triphenylamino, and carbazolylphenyl; When both R1 are phenyl, R2 and R3 can be 2-naphthyl, naphthylphenyl, arylanthracenyl, 9-phenanthryl, triphenylamino, or m-carbazolylphenyl.

Abstract translation: 提供了具有阳极，空穴注入层，光活性层，电子传输层和阴极的有机电子器件。 光活性层和电子传输层中的至少一个包括具有式I的化合物，其中：R 1相同或不同，可以是苯基，联苯基，萘基，萘基苯基，三苯基氨基或咔唑基苯基; 满足以下条件之一：（i）R2 = R3，为H，苯基，联苯基，萘基，萘基苯基，芳基蒽基，菲基，三苯基氨基或咔唑基苯基; 或（ii）R 2为H或苯基; 联苯基，萘基，萘基苯基，芳基蒽基，菲基，三苯基氨基和咔唑基苯基; 当R 1都是苯基时，R 2和R 3可以是2-萘基，萘基苯基，芳基蒽基，9-菲基，三苯基氨基或间 - 咔唑基苯基。

公开(公告)号：US09840512B2

公开(公告)日：2017-12-12

申请号：US14767815

申请日：2014-02-20

Applicant: Merck Sharp & Dohme Corp.

Inventor： Linda L. Brockunier ,  Helen Chen ,  Harry R. Chobanian ,  Matthew J. H. Clements ,  Alejandro Crespo ,  Duane E. DeMong ,  Yan Guo ,  William K. Hagmann ,  Karen M. Marcantonio ,  Michael Miller ,  Barbara Pio ,  Christopher W. Plummer ,  Dong Xiao

IPC: C07D311/04 ,  C07D311/28 ,  C07D491/052 ,  C07D493/04 ,  C07D201/00 ,  C07D405/14 ,  C07D319/20 ,  C07D405/04 ,  C07D405/06 ,  C07D405/10 ,  C07D413/10 ,  C07D417/04 ,  C07D491/048 ,  A61K31/352 ,  A61K31/416 ,  A61K31/422 ,  A61K31/427 ,  A61K31/436 ,  A61K31/4433 ,  A61K31/444 ,  A61K31/497 ,  A61K31/538 ,  A61K45/06

CPC classification number: C07D493/04 ,  A61K31/352 ,  A61K31/416 ,  A61K31/422 ,  A61K31/427 ,  A61K31/436 ,  A61K31/4433 ,  A61K31/444 ,  A61K31/497 ,  A61K31/538 ,  A61K45/06 ,  C07D201/00 ,  C07D311/04 ,  C07D311/28 ,  C07D319/20 ,  C07D405/04 ,  C07D405/06 ,  C07D405/10 ,  C07D405/14 ,  C07D413/10 ,  C07D417/04 ,  C07D491/048 ,  C07D491/052

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

公开(公告)号：US20170002040A1

公开(公告)日：2017-01-05

申请号：US15113773

申请日：2015-01-30

Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH ,  REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor： Michael P. Fautsch ,  Peter Dosa ,  Michael A. Walters ,  Gunda I. Georg

IPC: C07K5/062 ,  C07D405/14 ,  C07F9/6558 ,  C07D285/24 ,  C07D311/70 ,  C07D311/20 ,  C07F9/6547 ,  C07D405/04 ,  C07D405/12

CPC classification number: C07K5/06026 ,  A61K9/00 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/353 ,  A61K31/4025 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/549 ,  A61K31/675 ,  C07D201/00 ,  C07D285/24 ,  C07D311/20 ,  C07D311/70 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07F9/6547 ,  C07F9/65586

Abstract: The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure.

Abstract translation: 本发明提供苯并噻二嗪和苯并二氢吡喃衍生物，特别是用于治疗青光眼，视网膜病变，治疗年龄相关性黄斑变性，治疗，稳定和/或抑制血液和淋巴血管形成的二氮嗪和色氨酸衍生物，以及通过施用药学有效量降低眼内压 将前药置于眼睛上可接受的载体中，其中前药专门调节KATP通道以降低眼内压。

公开(公告)号：US20160002255A1

公开(公告)日：2016-01-07

申请号：US14767815

申请日：2014-02-20

Applicant: Linda L. BROCKUNIER ,  Helen CHEN ,  Harry R. CHOBANIAN ,  Matthew J. CLEMENTS ,  Alejandro CRESPO ,  Duane E. DEMONG ,  Yan GUO ,  William K. HAGMANN ,  Karen M. MARCANTONIO ,  Michael MILLER ,  Barbara PIO ,  Christopher W. PLUMMER ,  Dong XIAO ,  MERCK SHARP & DOHME CORP.

Inventor： Linda L. Brockunier ,  Helen Chen ,  Harry R. Chobanian ,  Matthew J. H. Clements ,  Alejandro Crespo ,  Duane E. DeMong ,  Yan Guo ,  William K. Hagmann ,  Karen M. Marcantonio ,  Michael Miller ,  Barbara Pio ,  Christopher W. Plummer ,  Dong Xiao

IPC: C07D493/04 ,  A61K31/352 ,  C07D405/04 ,  A61K31/4433 ,  C07D311/28 ,  C07D417/04 ,  A61K31/427 ,  C07D491/052 ,  A61K31/436 ,  C07D405/14 ,  A61K31/444 ,  C07D413/10 ,  A61K31/422 ,  C07D405/10 ,  A61K31/416 ,  A61K31/497 ,  A61K31/538 ,  A61K45/06 ,  C07D311/04

CPC classification number: C07D493/04 ,  A61K31/352 ,  A61K31/416 ,  A61K31/422 ,  A61K31/427 ,  A61K31/436 ,  A61K31/4433 ,  A61K31/444 ,  A61K31/497 ,  A61K31/538 ,  A61K45/06 ,  C07D201/00 ,  C07D311/04 ,  C07D311/28 ,  C07D319/20 ,  C07D405/04 ,  C07D405/06 ,  C07D405/10 ,  C07D405/14 ,  C07D413/10 ,  C07D417/04 ,  C07D491/048 ,  C07D491/052

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Abstract translation: 结构式（I）的新型化合物及其药学上可接受的盐是G蛋白偶联受体40（GPR40）的激动剂，可用于治疗，预防和抑制G蛋白偶联受体 受体40.本发明的化合物可用于治疗2型糖尿病，以及通常与该疾病相关的病症，包括肥胖症和脂质疾病，例如混合或糖尿病性血脂异常，高脂血症，高胆固醇血症和 高甘油三酯血症

公开(公告)号：US20100207108A1

公开(公告)日：2010-08-19

申请号：US12644362

申请日：2009-12-22

Applicant: Norman Herron ,  Mark A. Guidry ,  Vsevolod Rostovtsev ,  Weiying Gao ,  Ying Wang ,  Yulong Shen ,  Jeffrey A. Merlo

Inventor： Norman Herron ,  Mark A. Guidry ,  Vsevolod Rostovtsev ,  Weiying Gao ,  Ying Wang ,  Yulong Shen ,  Jeffrey A. Merlo

IPC: H01L51/54 ,  C07D471/04

CPC classification number: C07D471/04 ,  C07D201/00 ,  C07D471/16 ,  H01L51/0061 ,  H01L51/0072 ,  H01L51/5012 ,  H01L51/5024 ,  H01L51/5052 ,  H01L51/5072 ,  H01L2251/5384

Abstract: There is provided an organic electronic device having an anode, a hole injection layer, a photoactive layer, an electron transport layer, and a cathode. At least one of the photoactive layer and the electron transport layer includes a compound having Formula I where: R1 is the same or different and can be phenyl, biphenyl, naphthyl, naphthylphenyl, triphenylamino, or carbazolylphenyl; and one of the following conditions is met: (i) R2═R3 and is H, phenyl, biphenyl, naphthyl, naphthylphenyl, arylanthracenyl, phenanthryl, triphenylamino, or carbazolylphenyl; or (ii) R2 is H or phenyl; and R3 is phenyl, biphenyl, naphthyl, naphthylphenyl, arylanthracenyl, phenanthryl, triphenylamino, and carbazolylphenyl; When both R1 are phenyl, R2 and R3 can be 2-naphthyl, naphthylphenyl, arylanthracenyl, 9-phenanthryl, triphenylamino, or m-carbazolylphenyl.

Abstract translation: 提供了具有阳极，空穴注入层，光活性层，电子传输层和阴极的有机电子器件。 光活性层和电子传输层中的至少一个包括具有式I的化合物，其中：R 1相同或不同，可以是苯基，联苯基，萘基，萘基苯基，三苯基氨基或咔唑基苯基; 并且符合以下条件之一：（i）R 2 = R 3且为H，苯基，联苯基，萘基，萘基苯基，芳基蒽基，菲基，三苯基氨基或咔唑基苯基; 或（ii）R 2为H或苯基; 联苯基，萘基，萘基苯基，芳基蒽基，菲基，三苯基氨基和咔唑基苯基; 当R 1都是苯基时，R 2和R 3可以是2-萘基，萘基苯基，芳基蒽基，9-菲基，三苯基氨基或间 - 咔唑基苯基。

公开(公告)号：US4416818A

公开(公告)日：1983-11-22

申请号：US309958

申请日：1981-10-09

Applicant: Graham S. Poindexter

Inventor： Graham S. Poindexter

IPC: C07D201/00 ,  C07D207/26 ,  C07D207/263 ,  C07D263/22 ,  C07D207/12

CPC classification number: C07D207/27 ,  C07D201/00 ,  C07D263/22

Abstract: N-alkoxycarbonyl-substituted cyclic lactams and nitrogen-containing cyclic ketones are prepared by reaction of a C.sub.1-20 alkyl ester of trichloroacetic acid with the corresponding cyclic lactam or nitrogen-containing cyclic ketone.

Abstract translation: N-烷氧基羰基取代的环状内酰胺和含氮环状酮通过三氯乙酸的C 1-20烷基酯与相应的环状内酰胺或含氮环状酮反应来制备。